Virtual Library

Start Your Search

S. Wang



Author of

  • +

    Poster Session (ID 8)

    • Event: ACLC 2018
    • Type: Poster Session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 11/07/2018, 00:00 - 00:00, Poster Hall
    • +

      P106 - The Efficacy and Safety of Bevacizumab Combined with Chemotherapy in the Treatment of Drug-Resistant SCLC (ID 153)

      00:00 - 00:00  |  Author(s): S. Wang

      • Abstract

      Background:
      To explore the efficacy and safety of bevacizumab combined with chemotherapy in the treatment of drug-resistant small cell lung cancer (SCLC).


      Method:



      Results:
      Of the 25 patients, 5 patients achieved partial response, 16 patients achieved stable disease, 4 patients achieved progressive disease, and no patients achieved complete response. The short-term effective rate was 20% (5/25) and the clinical benefit rate was 84% (21/25). PFS ranged from 2 months to 6.3 months, and the median PFS was 3.7 months. OS ranged from 5.0 to 12.0 months, with a median OS of 7.6 months. Five patients were still alive as of April 10, 2018. Common toxic and side effects are myelosuppression, alimentary tract reaction and alopecia.


      Conclusion:
      Bevacizumab combined with chemotherapy is effective in the treatment of drug-resistant small cell lung cancer, and its side effects are tolerable. However, due to the small number of cases observed, the results are biased to a certain extent, it is necessary to establish a large-scale, randomized, double-blind, controlled multi-center clinical study to further confirm its efficacy and safety.